MedTrace Logo

Post-needling Soreness After Internal Gastrocnemius Muscle Treatment

NCT04060576 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2020-01-22

No results posted yet for this study

Summary

Mechanical hyperalgesia areas, also known as myofascial trigger points, are treated by manual therapy or invasive technics. Dry needling achieves an improvement of the symptomatology in 70% of the subjects, being the acute patients the most benefited. However, bruising, bleeding, pain during treatment or post-needling soreness. Plantar fasciitis is the most common cause of interior heel pain, affects approximately 10% of the general population and is one of the most benefited pathologies in the long term by the application of dry needling The gauge of the needle chosen for the treatment can influence post-needling soreness intensity and pressure pain threshold.

Objective To evaluate the relation between post-needling soreness intensity and needle diameter on the treatment of the most hyperalgesic point of the internal gastrocnemius.

Hypothesis Post-needling soreness intensity and pressure pain threshold depend on needle diameter applied in the treatment of the most hyperalgesic point of the internal gastrocnemius.

Conditions

  • Heel Pain Syndrome

Interventions

PROCEDURE

Dry needling treatment with a thinner needle

We will make an application with the dry needling technique with a fine needle on the myofascial trigger points of the gastrocnemius muscle.

PROCEDURE

Dry needling treatment with a medium-sized needle

We will make an application with the dry needling technique with a medium-sized needle on the myofascial trigger points of the gastrocnemius muscle.

PROCEDURE

Dry needling treatment with a thickest needle

We will make an application with the dry needling technique with the thickest needle on the myofascial trigger points of the gastrocnemius muscle.

Sponsors & Collaborators

  • University of Alcala

    lead OTHER

Principal Investigators

  • Tomas Gallego-Izquierdo, Dr · Alcala University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-08
Primary Completion
2019-12-16
Completion
2020-01-20

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04060576 on ClinicalTrials.gov